Blue Fin Capital Inc. decreased its stake in PetMed Express, Inc. (NASDAQ:PETS) by 19.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,015 shares of the company’s stock after selling 1,985 shares during the period. Blue Fin Capital Inc.’s holdings in PetMed Express were worth $325,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in PETS. Westside Investment Management Inc. boosted its stake in PetMed Express by 15.8% in the first quarter. Westside Investment Management Inc. now owns 5,502 shares of the company’s stock valued at $114,000 after buying an additional 752 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in PetMed Express by 76.7% in the second quarter. State of Alaska Department of Revenue now owns 4,028 shares of the company’s stock valued at $163,000 after buying an additional 1,748 shares in the last quarter. Group One Trading L.P. acquired a new stake in PetMed Express during the first quarter valued at about $174,000. Arizona State Retirement System boosted its stake in PetMed Express by 0.9% in the first quarter. Arizona State Retirement System now owns 10,667 shares of the company’s stock valued at $215,000 after buying an additional 100 shares in the last quarter. Finally, Weatherly Asset Management L. P. acquired a new stake in PetMed Express during the second quarter valued at about $216,000. Hedge funds and other institutional investors own 78.36% of the company’s stock.

PetMed Express, Inc. (NASDAQ:PETS) opened at 47.76 on Friday. PetMed Express, Inc. has a 52 week low of $18.90 and a 52 week high of $50.90. The company has a market capitalization of $969.15 million, a price-to-earnings ratio of 36.74 and a beta of 0.99. The company’s 50-day moving average price is $43.59 and its 200-day moving average price is $30.19.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings data on Monday, July 24th. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.07. PetMed Express had a return on equity of 28.67% and a net margin of 10.34%. The company had revenue of $79.66 million during the quarter, compared to analyst estimates of $77.32 million. During the same period in the previous year, the business earned $0.32 EPS. PetMed Express’s quarterly revenue was up 9.9% on a year-over-year basis. Equities analysts forecast that PetMed Express, Inc. will post $1.44 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 18th. Shareholders of record on Monday, August 7th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, August 3rd. This represents a $0.80 annualized dividend and a yield of 1.68%. PetMed Express’s dividend payout ratio (DPR) is currently 61.54%.

WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/13/blue-fin-capital-inc-has-325000-stake-in-petmed-express-inc-nasdaqpets.html.

A number of brokerages recently commented on PETS. Northcoast Research raised PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 price target for the company in a research note on Monday, July 24th. Zacks Investment Research raised PetMed Express from a “hold” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research note on Wednesday, May 10th. Noble Financial reissued a “hold” rating on shares of PetMed Express in a research note on Wednesday, July 26th. Finally, Craig Hallum lowered PetMed Express from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $35.00.

In other PetMed Express news, Director Frank J. Formica sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $35.32, for a total transaction of $176,600.00. Following the completion of the sale, the director now directly owns 46,000 shares in the company, valued at approximately $1,624,720. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Bruce S. Rosenbloom sold 6,833 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.18, for a total value of $342,879.94. Following the sale, the chief financial officer now owns 18,534 shares of the company’s stock, valued at $930,036.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,333 shares of company stock valued at $1,126,330. 4.00% of the stock is owned by company insiders.

PetMed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetMed Express, Inc. (NASDAQ:PETS).

Institutional Ownership by Quarter for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.